More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
AUM
$504591221
P/E ratio
24.8
Dividend yield
0.3726%
Expense ratio
0.35%
Beta
0.69672
Previous close
$248.82
Today's open
$248
Day's range
$246.08 - $249.27
52 week range
$179.25 - $263.74
show more
Headquarters
US
Exchange
NASDAQ Global Market
Issue type
Exchange-Traded Fund
Industries
Health
AMGN
Amgen Inc.
16.54%
14.31%
8.33%
7.54%
MRNA
Moderna Inc
6.62%
NTRA
Natera Inc
4.68%
4.21%
4.05%
3.73%
ILMN
Illumina, Inc.
3.31%
Should You Invest in the VanEck Biotech ETF (BBH)?
Launched on December 20, 2011, the VanEck Biotech ETF (BBH) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity market.
Zacks Investment Research • Nov 17, 2026

Simplify Health Care ETF vs. VanEck Biotech ETF: One Critical Difference Could Shape Future Returns
Simplify Health Care ETF uses active management to invest across the broader healthcare industry. VanEck Biotech ETF concentrates on 25 biotechnology companies and carries a lower expense ratio.
The Motley Fool • Nov 12, 2026

Democrats Sweep Midterms: What It Means For Pharma And Biotech Holdings (Stocks To Watch)
U.S. midterm results signal a "Blue Wave," with Democrats controlling both House and Senate, likely impacting healthcare policy and funding. Health insurers like UnitedHealth and CVS Health typically rebound after policy shocks; Oscar Health stands out for ACA-driven growth and innovation.
Seeking Alpha • Nov 5, 2026

ETFs That You May Consider Amid a Strengthening Biotech Outlook
Drug innovation, AI and rising M&A activity are boosting biotech optimism. Discover ETFs offering exposure to the sector.
Zacks Investment Research • Oct 28, 2026

Why Healthcare ETFs Are Hovering Around One-Year Highs
Healthcare ETFs are hovering near 52-week highs as earnings prospects improve, clinical breakthroughs advance and GLP-1 demand expands. Explore five ETFs riding the rally.
Zacks Investment Research • Oct 23, 2026

Biotech ETF (BBH) Hits New 52-Week High
For investors seeking momentum, VanEck Biotech ETF BBH is probably on the radar. The fund just hit a 52-week high and has risen 41.1% from its 52-week low price of $176.30/share.
Zacks Investment Research • Oct 21, 2026

Better Biotechnology ETF: First Trust FBT vs. VanEck BBH
The First Trust NYSE Arca Biotechnology Index Fund has outperformed the VanEck Biotech ETF on a one-year basis and over the last five years. The VanEck Biotech ETF offers a lower expense ratio of 0.35% compared to 0.55% for the First Trust fund.
The Motley Fool • Oct 10, 2026

Fidelity Healthcare ETF (FHLC) vs. VanEck Biotech ETF (BBH): Which Fund Is the Better Buy?
FHLC features a much lower expense ratio of 0.08% compared to 0.35% for BBH. BBH is a concentrated portfolio of just 26 stocks, while FHLC holds around 350 companies.
The Motley Fool • Sep 24, 2026

Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate
Biotech ETFs offer diversified exposure to oncology innovation as cancer funding surges and the global oncology drug market expands.
Zacks Investment Research • Sep 21, 2026

Retension Pharmaceuticals, TRex Bio file for US IPO as biotech momentum continues
Drug developers Retension Pharmaceuticals and TRex Bio filed their paperwork for U.S. initial public offerings on Friday, reinforcing the biotech pipeline for the fall IPO window.
Reuters • Sep 18, 2026

¹ Disclosures

Open an M1 investment account to buy and sell VanEck Vectors Biotech ETF commission-free¹. Build wealth for the long term using automated trading and transfers.